✨ Free AI Report
Acelyrin Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Acelyrin Inc.
Company Research

Acelyrin Inc.: Business Overview, Financials & Competitive Analysis

Acelyrin was a late-stage clinical biopharma company focused on immune-mediated diseases that completed a merger with Alumis in May 2025, with ACELYRIN stock ceasing to trade on NASDAQ. The company focused on accelera...

Analyst-debate audio for Acelyrin Inc.

AskCyborg analysts argue the bull and bear cases for Acelyrin Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
5/ 10Mixed

Cyborg Score thesis

Acelyrin's immunology assets are now part of Alumis, blending precision analytics with late-stage clinical programs in...

Read the full analyst-debate transcript →
Industry Immunology Drugs
2 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: November 16, 2026
AI-Generated Research
30+ Page Report

Get the Latest Acelyrin Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Acelyrin Inc. Overview

Pro stress-test →

Acelyrin was a late-stage clinical biopharma company focused on immune-mediated diseases that completed a merger with Alumis in May 2025, with ACELYRIN stock ceasing to trade on NASDAQ. The company focused on accelerating the development and commercialization of medicine, primarily in the field of immunology.

Strategic Profile

Pro stress-test →

Acelyrin's pipeline was led by izokibep, a small therapeutic protein inhibitor of interleukin-17A (IL-17A) designed to overcome the limitations of monoclonal antibodies. Through the merger with Alumis, the combined company gained financial flexibility and runway to advance an expanded late-stage pipeline, now including lonigutamab.

Competitive Landscape

Pro stress-test →

As of July 2026, Acelyrin no longer operates as an independent company. However, its former pipeline focused on IL-17A inhibition and thyroid eye disease treatment competed with companies developing targeted immunology therapies.

Industry Context

Acelyrin Inc. operates in Immunology Drugs.

Key facts

Founded: 2020 · Headquarters: Agoura Hills, CA, US · Employees: N/A · Revenue: N/A · Market cap: N/A (Acquired)

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Acelyrin Inc..

  • Acelyrin was co-founded in 2020 by Shao-Lee Lin and Bob Carey, combining physician-scientist and biopharma business development expertise
  • The company secured $250 million in Series B financing in November 2021, followed by a $300 million Series C round in September 2022
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2025Announced definitive merger agreement with Alumis Inc.
  • May 2025Completed merger with Alumis; ACELYRIN stock delisted from NASDAQ
Get alerted when Acelyrin Inc. has a new material development →

Compare Acelyrin Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Acelyrin Inc. operates in Immunology Drugs. See how the rest of the sector scores on the Cyborg framework.

Browse Immunology Drugs research →
NEW · MCP server

Ask your AI assistant about Acelyrin Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Acelyrin Inc. and its top competitor on Cyborg Score”
“What did Acelyrin Inc. do this quarter?”
“Is Acelyrin Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does Acelyrin Inc. do?+
Acelyrin was a late-stage clinical biopharma company focused on immune-mediated diseases that completed a merger with Alumis in May 2025, with ACELYRIN stock ceasing to trade on NASDAQ. The company focused on accelera...
What is Acelyrin Inc.'s Cyborg Score?+
Acelyrin Inc. has a Cyborg Score of 5/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Acelyrin Inc.'s main competitors?+
The full competitive landscape for Acelyrin Inc. is in the AskCyborg report.
How can I get the full Acelyrin Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Acelyrin Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Acelyrin Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual